SCHEMBL4158152

SCHEMBL4158152

Cc1cccc(C)c1NC(=O)c1ccnc2[nH]c(-c3ccc(NCCN4CCOCC4)cc3)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
POLB P06746 1/20 0.44
LCK P06239 4/20 0.43
MAPK14 Q16539 3/20 0.43
PLK1 P53350 1/20 0.41
HSD17B10 Q99714 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
KDM4E B2RXH2 3/20 0.41
RAB9A P51151 3/20 0.41
HTT P42858 1/20 0.41
GSK3B P49841 1/20 0.41
PTGES O14684 1/20 0.40
NPC1 O15118 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4150322 0.88 KDM4E (0.47) ALDH1A1POLBPLK1HSD17B10CYP2C19
SCHEMBL4161803 0.87 GSK3B (0.47) ALDH1A1LCKMAPK14KDM4ERAB9A
SCHEMBL4160369 0.83 GSK3B (0.46) ALDH1A1POLBLCKMAPK14KDM4E
SCHEMBL4150315 0.82 CNR2 (0.48) RAB9ANPC1SMN1; SMN2
SCHEMBL4152692 0.82 CNR2 (0.48) RAB9ANPC1SMN1; SMN2
SCHEMBL4156499 0.81 MERTK (0.44) LCKMAPK14GSK3BTYK2KDR
SCHEMBL4167122 0.79 PBK (0.42) ALDH1A1LCKHSD17B10KDM4ERAB9A
SCHEMBL13778196 0.79 ALDH1A1 (0.44) ALDH1A1LCKMAPK14PLK1HSD17B10
SCHEMBL4152887 0.79 CNR2 (0.42) ALDH1A1PLK1KDM4ERAB9AHTT
SCHEMBL8237367 0.79 GSK3B (0.49) ALDH1A1POLBHSD17B10KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 ALDH1A1 4274/4885POLB 2169/4885LCK 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.